Alvotech
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVO research report →
Range $8 – $9
Price Chart
About the company
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
- CEO
- Lisa Graver
- IPO
- 2022
- Employees
- 1,279
- HQ
- Luxembourg, LU, LU
Get TickerSpark's AI analysis on ALVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.47B
- P/E
- -5.71
- Fwd P/E
- 16.74
- PEG
- 0.06
- P/S
- 3.32
- P/B
- -5.58
- EV/EBITDA
- -313.19
- Div Yield
- 0.00%
- Gross Margin
- 56.81%
- Op Margin
- 11.98%
- Net Margin
- -50.93%
- ROE
- 97.21%
- ROIC
- 4.20%
Latest fiscal year · YoY change
- Revenue
- $586.32M+19.7%
- Gross Profit
- $350.76M+15.2%
- Op Income
- $78.21M
- Net Income
- $27.92M+112.0%
- EPS
- $0.10+111.5%
- OCF Growth
- +78.8%
- FCF Growth
- +61.0%
- 52W High
- $6.53
- 52W Low
- $2.94
- 50D MA
- $5.16
- 200D MA
- $4.17
- Beta
- 0.18
- RSI (14)
- 40
- Avg Volume
- 1.16M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alvotech said Q3 improved as supply recovered, but full-year revenue and EBITDA are now expected near the low end of guidance while the company pointed to a strong Q4 and multiple regulatory catalysts ahead.· November 12, 2026
- Q3 total revenue was $112 million, down 2% year over year but up 5% sequentially; adjusted EBITDA was $31 million, up 40% quarter over quarter and double last year.
- For the first 9 months, revenue was $323 million and adjusted EBITDA was $78 million, up 15% year over year; gross margin was 54% for both Q3 and the 9-month period.
- Management said the business is still ramping after manufacturing slowdowns, but product revenue recovery is evident, with Q3 product and service revenue at $58 million, up 78% year over year.
- The company received two FDA approvals in October for Simlandi manufacturing capacity and Process 2.0, which management said doubles drug substance output per batch.
- Several pipeline and commercialization milestones are approaching, including Entyvio and high-dose Eylea reviews, and a Lotus deal that could bring up to about $150 million in upfront and milestone payments.
Reported figures: Q3 total revenue was $112 million, down 2% year over year and up 5% sequentially; Q3 adjusted EBITDA was $31 million, up 40% quarter over quarter and 100% year over year; Q3 gross margin was 54%, up 3 percentage points sequentially. For the first 9 months of 2026, revenue was $323 million, down 23% year over year; gross margin was 54%, down 5 percentage points year over year; adjusted EBITDA was $78 million, up 15% year over year and equal to a 24% margin. Product and service revenue was $58 million in Q3, up 78% year over year and 6% sequentially; first-9-month product revenue was $164 million and licensing revenue was $159 million. Cash on hand at the end of the period was $61 million, down from $143 million at the beginning of the quarter. Full-year 2026 guidance was reiterated at revenue of $650 million to $700 million and adjusted EBITDA of $180 million to $220 million, but management said performance now trends toward the lower end of those ranges. Management also said Q4 is expected to be the strongest quarter of the year and that cash flow is expected to turn positive in Q4 2026.
Robert Wessman framed the quarter as a turning point, saying Alvotech has built a strong commercial portfolio, a manufacturing base in Iceland, and one of the strongest biosimilar pipelines in the industry. He highlighted expected FDA approvals on three products before year-end, the strength of the Entyvio and high-dose Eylea programs, and the new Lotus partnership as evidence that the company is capturing more of the value chain. His tone was upbeat and strategic, emphasizing that Alvotech is entering an inflection point with a strong order book into 2027.
Linda Jonsdottir focused on the financial recovery from the earlier manufacturing slowdown. She said Q3 improved across revenues, gross margin, product margin, and adjusted EBITDA, with total revenue of $112 million, gross margin of 54%, and adjusted EBITDA of $31 million; for the first 9 months, revenue was $323 million and adjusted EBITDA was $78 million, with a 24% margin. She explained that cash used in operations was $89 million in the quarter, driven mainly by $116 million of working capital absorption as the company ramped inventory and prepared for launches, while net interest payments were $37 million and investments in intangibles were $32 million. She also said the 2026 outlook remains $650 million to $700 million of revenue and $180 million to $220 million of adjusted EBITDA, but now toward the lower end, and noted healthy deleveraging is expected in the second half of 2027.
Analysts focused on the timing and risk of key launches, especially Simponi and Entyvio, plus the implications of recent Eylea legal and patent developments. Management said it remains confident in its legal positions on Simponi and AVT29/Eylea, and described Teva as a committed partner, but would not commit to exact launch timing because of litigation and regulatory uncertainty. On Entyvio, management said it believes it will be in the first wave and sees healthy volume and margin potential in the US. On 2027, management said it expects substantial improvement versus 2026 but declined to give formal guidance; it also said Q4 2026 should be cash-flow positive and that deleveraging should become more meaningful in late 2027.
The call points to a clear operating recovery: product revenue is rebounding, Simlandi manufacturing capacity has expanded, and management expects Q4 to be the strongest quarter in company history. The pipeline also looks active, with Entyvio and high-dose Eylea under review and the Lotus deal potentially adding up to about $150 million in payments plus new US commercialization optionality.
Management repeatedly said 2026 results are still being affected by prior manufacturing disruptions, with revenue and EBITDA now expected near the low end of guidance and gross margin still under pressure from earlier facility work. Cash was down to $61 million at quarter-end, operating cash use remained elevated because of working capital ramp, and several important revenue catalysts depend on regulatory decisions and litigation outcomes that are not yet resolved.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 30.5%
- Shares Outstanding
- 356.82M
- Float Shares
- 108.89M
of shares held by institutions
73 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Rubric Capital Management LP | 19.76M | ▲ 4.08M |
| Vanguard Capital Management LLC | 5.28M | ▲ 1.59M |
| Vanguard Group Inc | 4.49M | ▲ 141.95K |
| Bracebridge Capital, LLC | 4.04M | 0 |
| Millennium Management LLC | 3.18M | ▼ 1.08M |
| Farallon Capital Management, L.L.C. | 2.86M | 0 |
| Citadel Advisors LLC | 2.78M | ▲ 1.05M |
| Point72 Asset Management, L.P. | 2.61M | ▲ 2.61M |
| Blackrock, Inc. | 1.96M | ▲ 628.93K |
| Vanguard Fiduciary Trust Co | 1.54M | ▲ 543.42K |
| Littlejohn & Co LLC | 1.32M | 0 |
| Legal & General Group PLC | 843.75K | ▲ 147.71K |
Held by 168 ETFs
Biggest fund positions in ALVO by dollar value.
Our ALVO coverage
Recent articles, reports, and earnings notes.
No research on ALVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVO report →Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
What Alvotech (ALVO) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 11
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
globenewswire.com · Nov 11
Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know
zacks.com · Nov 4
Alvotech: The Market Is Still Pricing The Broken Factory
seekingalpha.com · Nov 3
Alvotech to Present at Upcoming Investor Conferences in November
globenewswire.com · Nov 2
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
globenewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.